Press Room

DDF - 15th American Drug Delivery & Formulation Summit

Start
Monday, September 15, 2025
End
Tuesday, September 16, 2025
Location: Boston, United States
Booth Number: Table #17



Hovione is exhibiting at the American Drug Delivery & Formulation Summit (DDF), an event that will once again bring together over 300 scientific leaders from pharma, biotech, and drug delivery industries. This edition features two days of presentations with an exceptional line-up of the industry's best speakers, including a Technology and Innovation Session led by Hovione experts.

Meet the Hovione team in Boston and don’t miss our Technology & Innovation Session

“Spray Drying of Biologics: Unlocking Full Potential through Formulation and Particle Engineering”

 

Spray drying is increasingly recognized as an enabling technology in drug product development, offering distinct advantages in particle engineering, stabilization, and enhancement of bioavailability. Although traditionally viewed as a challenging approach for biologics, recent advances in formulation science and process optimization have significantly broadened its applicability, paving the way for innovative formulation platforms across multiple delivery routes.

On September 15, in a session led by our R&D Director, João Pires, discover firsthand how spray drying has been successfully applied to develop robust and scalable biopharmaceutical formulation platforms.

Interested in knowing how we can ensure the stability and performance of your biologic drug product? Speak with our experts and learn how our extensive knowledge and experience can support your project from early stages of development to commercialization.

schedule a meeting

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026